Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CARRIE W COBB

Allopathic & Osteopathic Physicians Dermatology

NPI
1770732232
CMS profile
612830
Location
LYNCHBURG, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,576.76

71 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,546.76 70
Education $30.00 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CARRIE W COBB

NPI 1770732232 · CMS profile ID 612830

Allopathic & Osteopathic Physicians / Dermatology

LYNCHBURG, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770732232?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CARRIE W COBB, NPI 1770732232, CMS profile ID 612830. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770732232?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CARRIE W COBB, NPI 1770732232, CMS profile ID 612830. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770732232?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CARRIE W COBB, NPI 1770732232, CMS profile ID 612830, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1770732232?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

71 matching records · $1,576.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 71 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–71 of 71.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $23.0103/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648096485 CMS
PFIZER INC. $14.7903/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671922721 CMS
GENZYME CORPORATION $89.8903/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693989361 CMS
AbbVie, Inc. $21.8103/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648096483 CMS
AbbVie, Inc. $63.9803/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648096473 CMS
Novartis Pharmaceuticals Corporation $16.6503/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658871885 CMS
PFIZER INC. $13.2202/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671922573 CMS
PFIZER INC. $12.1702/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671872739 CMS
UCB, Inc. $21.2002/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688256947 CMS
Lilly USA, LLC $15.9802/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657704135 CMS
Novartis Pharmaceuticals Corporation $16.5902/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658871919 CMS
AbbVie, Inc. $18.9302/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648096471 CMS
GENZYME CORPORATION $22.1402/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693909225 CMS
PruGen, Inc. Pharmaceuticals $12.3301/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707758553 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $14.5601/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684572151 CMS
Novartis Pharmaceuticals Corporation $22.6901/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658871893 CMS
PFIZER INC. $13.5101/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671855593 CMS
AbbVie, Inc. $23.8901/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648096459 CMS
UCB, Inc. $19.3901/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688247745 CMS
Celgene Corporation $16.7701/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672716211 CMS
LEO Pharma Inc. $30.0001/02/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687256437 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,576.76 71
PY2020 $452.78 24
PY2021 $756.82 43
PY2022 $1,473.25 82
PY2023 $1,140.39 66
PY2024 $1,276.84 63
PY2025 $1,300.92 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,925.00 1
PY2025 Principal investigator $114,849.62 28
PY2024 Principal investigator $62,328.66 17
PY2023 Principal investigator $244,801.75 20
PY2022 Principal investigator $429,473.77 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,996.80 12/31/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228725332
Principal investigator 1 Vanda Pharmaceuticals Inc. $10,815.00 12/17/2025 Non-covered Recipient Entity
THE EDUCATION & RESEARCH FOUNDATION
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232947192
Principal investigator 1 ABBVIE INC. $9,832.49 11/12/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202523809
Principal investigator 1 PFIZER INC. $2,919.80 10/29/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228756677
Principal investigator 1 Vanda Pharmaceuticals Inc. $9,090.00 10/28/2025 Non-covered Recipient Entity
THE EDUCATION & RESEARCH FOUNDATION
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946752
Principal investigator 1 PFIZER INC. $200.00 10/22/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228756407
Principal investigator 1 SANOFI PASTEUR INC. $2,947.82 10/07/2025 Non-covered Recipient Entity
The Research And Education Institute For Thr
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226101787
Principal investigator 1 Vanda Pharmaceuticals Inc. $7,445.00 10/03/2025 Non-covered Recipient Entity
THE EDUCATION & RESEARCH FOUNDATION
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946440
Principal investigator 1 PFIZER INC. $1,188.85 10/01/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228724544
Principal investigator 1 PFIZER INC. $961.35 09/26/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228753927
Principal investigator 1 PFIZER INC. $1,679.60 09/24/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228759877
Principal investigator 1 PFIZER INC. $1,996.80 09/19/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228749407
Principal investigator 1 PFIZER INC. $843.05 09/12/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228749909
Principal investigator 1 Vanda Pharmaceuticals Inc. $7,375.00 09/04/2025 Non-covered Recipient Entity
THE EDUCATION & RESEARCH FOUNDATION
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946228
Principal investigator 1 PFIZER INC. $5,218.20 08/23/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228766931
Principal investigator 1 Vanda Pharmaceuticals Inc. $681.86 08/06/2025 Non-covered Recipient Entity
THE EDUCATION & RESEARCH FOUNDATION
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946031
Principal investigator 1 PFIZER INC. $1,257.75 08/05/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228766294
Principal investigator 1 PFIZER INC. $4,725.38 07/29/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228792012
Principal investigator 1 PFIZER INC. $5,091.48 07/17/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228724634
Principal investigator 1 Vanda Pharmaceuticals Inc. $6,000.00 07/03/2025 Non-covered Recipient Entity
THE EDUCATION & RESEARCH FOUNDATION
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232945657
Principal investigator 1 PFIZER INC. $1,440.00 07/02/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228792343
Recipient ABBVIE INC. $2,925.00 05/09/2025 Covered Recipient Physician A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars No dispute reported 06/30/2026 1202397747
Principal investigator 1 PFIZER INC. $2,919.80 05/06/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228763784
Principal investigator 1 Amgen Inc. $12,313.00 04/24/2025 Non-covered Recipient Entity
THE EDUCATION AND RESEARCH FOUNDATION
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246649440
Principal investigator 1 PFIZER INC. $843.05 04/09/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228723596
Principal investigator 1 Amgen Inc. $1,000.00 03/25/2025 Non-covered Recipient Entity
EDUCATION AND RESEARCH FOUNDATION INC
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) No dispute reported 06/30/2026 1246641053
Principal investigator 1 PFIZER INC. $1,257.75 03/14/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228796881
Principal investigator 1 PFIZER INC. $4,712.00 03/06/2025 Non-covered Recipient Entity
The Education Research Foundation Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228797508
Principal investigator 1 Amgen Inc. $8,097.79 01/30/2025 Non-covered Recipient Entity
EDUCATION AND RESEARCH FOUNDATION INC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246641055